A Study Testing the Use of a Perivascular Sirolimus Formulation (Sirogen) in ESRD Patients Undergoing AV Fistula Surgery

NCT ID: NCT05425056

Last Updated: 2025-09-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

136 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-08-26

Study Completion Date

2025-08-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary study objective is to evaluate the benefit of the Sirolimus eluting Collagen implant (SeCI; Sirogen), a single dose prophylactic treatment delivered intraoperatively at the time of surgical creation of an arteriovenous fistula for hemodialysis vascular access.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a Phase 3, multicenter, randomized, single-blind, controlled, study designed to evaluate the efficacy and safety of the use of the Sirolimus-eluting Collagen Implant (SeCI) in subjects who are on hemodialysis and are undergoing surgical creation of an AV fistula in comparison to subjects who do not receive the implant.

Subjects of either gender, who are at least 65 years of age, undergoing hemodialysis, and require a new single stage radiocephalic end to side fistula will be eligible to participate in this study. Subjects who meet eligibility criteria and undergo successful AV fistula creation will be eligible for enrollment. The study plans to enroll approximately 120 subjects, randomized in a 1:1 ratio. Enrolled subjects will be followed for a period of one year from the time of their index surgical procedure.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Complication of Renal Dialysis End Stage Renal Disease End Stage Kidney Disease ESRD Chronic Kidney Failure Complication of Hemodialysis Vascular Access Complication Arteriovenous Fistula

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Caregivers Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment Arm

Subjects randomized to the treatment arm will undergo AV fistula surgery and will receive the Sirolimus eluting Collagen Implant (SeCI).

Group Type EXPERIMENTAL

Sirolimus

Intervention Type DRUG

SeCI placed at and around the site of the anastomosis of an AV fistula, immediately following completion of a successful AV fistula surgery.

Control Arm

Subjects randomized to the control arm will undergo AV fistula surgery alone and will not receive an implant.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sirolimus

SeCI placed at and around the site of the anastomosis of an AV fistula, immediately following completion of a successful AV fistula surgery.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Sirolimus-eluting Collagen Implant SeCI Sirogen

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 65 years or older
* Currently on hemodialysis for ≤12 months
* Successful creation of a single stage radiocephalic end to side fistula

Exclusion Criteria

* Prior AV access created on the limb where the fistula surgery is planned
* Planned start of peritoneal dialysis within 6 months of randomization
* Known hypersensitivity to the following: sirolimus, beef or bovine collagen
* Known to be HIV positive
* Prisoner, mentally incompetent, and/or current alcohol or drug abuser
Minimum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Vascular Therapies, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Sriram Iyer, MD

Role: STUDY_DIRECTOR

Vascular Therapies, Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Veterans Affairs San Diego Health Center

San Diego, California, United States

Site Status

Lundquist Institute for Biomedical Innovation

Torrance, California, United States

Site Status

MedStar Cardiovascular Research Network at MedStar Washington Hospital Center

Washington D.C., District of Columbia, United States

Site Status

American Access Care of Miami

Miami, Florida, United States

Site Status

Emory University Hospital Midtown

Atlanta, Georgia, United States

Site Status

Augusta University

Augusta, Georgia, United States

Site Status

University of Louisville

Louisville, Kentucky, United States

Site Status

The Brigham and Women's Hospital

Boston, Massachusetts, United States

Site Status

Mount Sinai Hospital

New York, New York, United States

Site Status

Atrium Health

Charlotte, North Carolina, United States

Site Status

Surgical Specialists of Charlotte

Charlotte, North Carolina, United States

Site Status

The Regional Medical Center/Dialysis Access Institute

Orangeburg, South Carolina, United States

Site Status

James Eric Gardner, MD PC

Memphis, Tennessee, United States

Site Status

Arteries & Veins

El Paso, Texas, United States

Site Status

Houston Methodist

Houston, Texas, United States

Site Status

Houston Methodist

Sugar Land, Texas, United States

Site Status

Sentara Norfolk General Hospital/Sentara Health Research Center

Norfolk, Virginia, United States

Site Status

University Hospitals Birmingham NHS Foundation Trust

Birmingham, , United Kingdom

Site Status

St Helier Hospital

Carshalton, , United Kingdom

Site Status

NHS Greater Glasgow and Clyde

Glasgow, , United Kingdom

Site Status

Barts Health NHS Trust of Royal London Hospital

London, , United Kingdom

Site Status

St George's University Hospitals NHS Foundation Trust

London, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

VT-305

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Clinical Study of Aneurysm Exclusion
NCT00549380 UNKNOWN PHASE1